Adrian Parry

Adrian Parry is an accomplished professional with extensive experience in the pharmaceutical and biopharmaceutical industries. Currently serving as the Director of CMC at Aravax since June 2025, Parry previously held key roles including Head of Manufacturing at SCANCELL LIMITED, where oversight of GMP manufacturing activities and CMC regulatory submissions was provided. Prior to that, Parry worked as Head of Small Molecule CMC at MEREO BIOPHARMA GROUP PLC, focusing on the development and validation of small molecule manufacturing processes. Additional experience includes New Product Development Director at Juniper Pharmaceuticals, Analytical Development Manager at Circassia, and various leadership positions at Shire Pharmaceuticals, Prosidion Ltd, Aptuit, Evotec, and OSI Pharmaceuticals. Adrian Parry's educational background includes a PhD in Physical Organic Chemistry from The Open University, an MSc in Advanced Analytical Chemistry from the University of Bristol, and a BSc (Hons) in Chemistry from the University of Warwick.